Work

Ponatinib: An oral tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome -- positive acute lymphoblastic leukemia

Year: 2013

Type: article

Abstract: Ponatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia (CML) that is resistant or intolerant to previous TKI therapy, and for Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (Ph+ALL).

Source: Journal of Media Literacy Education

Author: Brett Feret

Institution: University of Rhode Island

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2117148929

FWCI:

Cites: 2

Cited by:

Related to: 10